Ma Xiaofeng, Xu Jin, Ye Xinhan, Yang Fangjia, Wang Zhong, Feng Jianju
Department of Radiology, Zhuji People's Hospital, Zhuji, Zhejiang 311800, P.R. China.
Oncol Lett. 2024 Jul 31;28(4):467. doi: 10.3892/ol.2024.14600. eCollection 2024 Oct.
Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare subtype of renal cancer. The present report details the treatment experience of a case of MTSCC, where the patient underwent a right-side laparoscopic nephrectomy in October 2020 at Zhuji People's Hospital (Zhuji, China). A total of 3 months post-operation, multiple metastases were discovered in the right renal area and retroperitoneum, with rapid disease progression observed in the subsequent 2 months. Treatment with tislelizumab combined with pazopanib was ineffective, and the patient subsequently died. Although MTSCC is generally considered a low-grade 'indolent' tumor, with most patients achieving long-term survival post-surgery, a minority of cases, especially those of a higher grade, may experience postoperative recurrence and metastasis. Due to the rarity of metastatic MTSCC, most studies are based on small sample sizes or case reports, and there is a lack of standardized systemic treatment and follow-up strategies for metastatic MTSCC. The present paper summarizes and analyzes the clinical features, treatment methods and prognosis of metastatic MTSCC cases reported in the literature, aiming to provide assistance for the treatment and follow-up management of metastatic MTSCC. Even in cases of distant metastasis, aggressive surgical treatment, metastasectomy combined with molecular targeted or immunotherapy, may still be recommended.
黏液性小管状和梭形细胞癌(MTSCC)是一种罕见的肾癌亚型。本报告详细介绍了一例MTSCC患者的治疗经历,该患者于2020年10月在诸暨市人民医院(中国诸暨)接受了右侧腹腔镜肾切除术。术后3个月,在右肾区和腹膜后发现多处转移,随后2个月病情迅速进展。替雷利珠单抗联合帕唑帕尼治疗无效,患者随后死亡。尽管MTSCC通常被认为是一种低级别“惰性”肿瘤,大多数患者术后可长期存活,但少数病例,尤其是高级别病例,可能会出现术后复发和转移。由于转移性MTSCC罕见,大多数研究基于小样本量或病例报告,且缺乏针对转移性MTSCC的标准化系统治疗和随访策略。本文总结并分析了文献报道的转移性MTSCC病例的临床特征、治疗方法和预后,旨在为转移性MTSCC的治疗和随访管理提供帮助。即使在远处转移的情况下,仍可能推荐积极的手术治疗,即转移灶切除术联合分子靶向治疗或免疫治疗。